This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| European Institute of Innovation and Technology Health | |
|---|---|
| Name | European Institute of Innovation and Technology Health |
| Native name | EIT Health |
| Founded | 2015 |
| Headquarters | Paris, France |
| Region served | Europe |
| Leader title | CEO |
| Leader name | Jean-Pierre Bourguignon |
| Parent organization | European Institute of Innovation and Technology |
European Institute of Innovation and Technology Health is a pan-European public-private partnership consortium focused on promoting innovation in healthcare across the European Union, European Economic Area, and associated countries. It operates as a Knowledge and Innovation Community within the European Institute of Innovation and Technology framework, connecting actors from academia, industry, and healthcare to accelerate translation of biomedical research, medical devices, digital health and pharmaceutical innovations into patient care. The organization engages with major research centers, universities, hospitals, and companies to deliver education, innovation projects, and business creation services.
EIT Health brings together partners such as Imperial College London, Karolinska Institutet, University of Oxford, Erasmus University Rotterdam, École Polytechnique, Technical University of Munich, University College London, Heidelberg University Hospital, Siemens Healthineers, Roche, Sanofi, Philips, Novartis, Bayer, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Medtronic, Boston Scientific, Cisco Systems, IBM, Google Health, Amazon Web Services, Microsoft, Oracle Corporation, Accenture, Deloitte, McKinsey & Company, KPMG, PwC, European Commission, European Parliament, Council of the European Union, World Health Organization, Organisation for Economic Co-operation and Development, European Medicines Agency, European Centre for Disease Prevention and Control, European Investment Bank, Horizon 2020, Horizon Europe, Marie Skłodowska-Curie Actions, CERN, École Normale Supérieure, Sorbonne University, University of Barcelona, KU Leuven, University of Cambridge, University of Milan, Politecnico di Milano, Trinity College Dublin, Dublin City University, University of Zurich, ETH Zurich, University of Copenhagen, Aalborg University, University of Helsinki, University of Oslo, University of Stockholm, Uppsala University, University of Warsaw, Jagiellonian University, Charles University, Masaryk University, University of Belgrade, University of Ljubljana', University of Zagreb', University of Lisbon'.
EIT Health was established following proposals by the European Commission and the High-Level Expert Group on the Competitiveness of the European Knowledge-Intensive Industries to strengthen innovation ecosystems across Europe and launched within the European Institute of Innovation and Technology cycle that created other Knowledge and Innovation Communities such as EIT Climate-KIC, EIT Digital, EIT RawMaterials, EIT Food, EIT Manufacturing, and EIT InnoEnergy. Founding partners included leading institutions like Karolinska Institutet, Imperial College London, EIT Health France stakeholders, and multinational firms including Roche and Philips, aligning with Horizon 2020 priorities and subsequent Horizon Europe agendas.
EIT Health’s mission aligns with strategic documents from European Commission President Ursula von der Leyen’s administration and seeks to stimulate entrepreneurship and health technology adoption. Key objectives reference delivering accelerated pathways from prototype to market, supporting start-up creation, scaling SMEs, fostering cross-border clinical validation with partners like NHS England, AP-HP (Assistance Publique–Hôpitaux de Paris), Charité – Universitätsmedizin Berlin, and supporting regulatory navigation in cooperation with European Medicines Agency and national competent authorities. It aims to contribute to priorities in the European Health Union initiative and the Digital Single Market.
EIT Health is governed through a Board of Stakeholders composed of representatives from industry partners, academic institutions, and healthcare providers including delegates from European Commission liaison offices, and advisory boards linking to European Innovation Council activities. Operational units include regional hubs across France, Germany, United Kingdom, Spain, Italy, Sweden, Denmark, Finland, Netherlands, Belgium, Portugal, Poland, and Hungary, coordinated with central management headquartered in Paris and legal registration influenced by French law. Leadership interacts with funding bodies such as the European Investment Bank and aligns strategic planning with programs like Erasmus+ and Cohesion Fund priorities.
EIT Health runs multiple programs: startup acceleration and innovation support similar to Startup Europe initiatives; education programs modeled on collaborative degrees like Erasmus Mundus and executive training paralleling offerings at INSEAD, HEC Paris, London Business School; clinical validation projects with university hospitals such as Addenbrooke's Hospital, Karolinska University Hospital, Hôpital Pitié-Salpêtrière; and pilot deployments in health systems including Société Générale de Santé networks. Programs emphasize digital therapeutics, connected care, precision medicine, AI applications akin to projects at DeepMind, regulatory science partnerships with European Medicines Agency, and health economics analyses comparable to work by OECD Health Division.
EIT Health maintains partnerships with supranational entities like the European Commission, Council of Europe, and World Health Organization, universities including University of Oxford, Karolinska Institutet, University of Cambridge, companies such as Philips and Roche, innovation intermediaries like Nesta, EIT Digital and EIT Climate-KIC, accelerator networks such as Techstars, MassChallenge, and investment groups including European Investment Fund, Sequoia Capital, Index Ventures, Atomico, Balderton Capital, Accel Partners, Northzone, Draper Esprit, Seedcamp, and numerous hospital consortia.
Funding streams combine co-financing from the European Institute of Innovation and Technology budget, partner contributions from industry giants like Sanofi, Novartis, GlaxoSmithKline, public grants from Horizon Europe, investment from European Investment Bank instruments, and revenue-generating services such as education fees and equity in start-ups. Financial oversight adheres to reporting standards referenced by European Court of Auditors guidance and internal audits influenced by practices at PricewaterhouseCoopers, Deloitte, and KPMG.
EIT Health reports outcomes including the acceleration of dozens of start-ups, deployment of digital health pilots, and creation of transnational training programs, with impact narratives compared to outputs from EIT Digital and EIT Climate-KIC. Criticisms mirror debates faced by other public-private partnerships: concerns voiced by think tanks like Bruegel and European Policy Centre about governance transparency, potential influence by large corporations such as Roche and Philips, and questions over alignment with public health priorities highlighted by advocates connected to European Public Health Alliance and Health Action International. Regulatory observers reference scrutiny by European Ombudsman-style bodies and parliamentary committees in European Parliament inquiries.
Category:European health organizations